Evidence map›Paper›PMID 41551829›Full record

ArticleWorld journal of gastroenterology2026

Beyond rheumatology: Reconsidering methotrexate for Crohn's disease in the biologic era.

Jun-Young Seo, Jun Hwan Yoo

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jun-Young SeoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, South Korea.
Jun Hwan YooDivision of Gastroenterology and Hepatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, South Korea. jhyoo@cha.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the pre-biologic era, immunomodulators such as azathioprine, 6-mercaptopurine, and methotrexate (MTX) were widely used as first-line maintenance therapies in Crohn's disease. However, in the current era shaped by biologics, their role has shifted toward adjunctive use, primarily in combination with anti-tumor necrosis factor agents to reduce immunogenicity. Amid growing concerns about thiopurine-associated risks, MTX is receiving renewed attention for its favorable safety profile; however, this agent remains inconsistently utilized in gastroenterology despite its frontline status in rheumatology. This discrepancy was highlighted in a recent nationwide survey by Bonnaud

Indexed as

Biological ProductsCrohn DiseaseImmunosuppressive AgentsMethotrexateDrug Therapy, CombinationGastroenterologistsGastroenterologyHumansPractice Patterns, Physicians'RheumatologyTreatment OutcomeBiological ProductsImmunosuppressive AgentsMethotrexateBiologicsClinical practiceCrohn’s diseaseImmunosuppressantsMethotrexate

Identifiers

PMID41551829
PMCPMC12809209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.